Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, China.
Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, China.
Cancer Gene Ther. 2023 Mar;30(3):507-520. doi: 10.1038/s41417-022-00572-0. Epub 2023 Jan 19.
Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional trajectory within each patient. The top 5 most frequently mutated genes in our study were TTN (76.74%), MUC16 (62.79%), MUC19 (55.81%), FRG1 (46.51%), and NBPF20 (46.51%). For most patients in our study, a substantial of genetic alterations were mutually exclusive among the multiple pulmonary tumors of the same patient, suggesting their heterogenous origins. Individually, the genetic profile of lymph node metastatic lesions overlapped with that of multiple lung cancers in different degrees but are more genetically related to specific pulmonary lesions. SETD2 was a potential metastasis biomarker of MPLC. The mean putative neo-antigen number of the primary tumor (646.5) is higher than that of lymph node metastases (300, p = 0.2416). Primary lung tumors and lymph node metastases are highly heterogenous in immune repertoires. Our findings portrayed the comprehensive genomic landscape of MPLC with LNM. We characterized the genomic heterogeneity among different tumors. We offered novel clues to the clonal evolution between MPLC and their lymphatic metastases, thus advancing the treatment strategies and preventions of MPLC with LNM.
多原发肺癌(MPLC)伴淋巴结转移(LNM)是多灶性肺癌的罕见现象。MPLC 的基因组景观以及原发性肺病变和淋巴结转移之间的克隆进化模式尚未完全阐明。我们对 11 例 MPLC 伴 LNM 患者的 52 个 FFPE(福尔马林固定石蜡包埋)样本进行了全外显子组测序(WES)。进行了基因组分析和系统发育分析,以推断每个患者内部的进化轨迹。我们的研究中最常突变的前 5 个基因是 TTN(76.74%)、MUC16(62.79%)、MUC19(55.81%)、FRG1(46.51%)和 NBPF20(46.51%)。对于我们研究中的大多数患者,同一患者的多个肺部肿瘤之间存在大量的遗传改变是相互排斥的,这表明它们具有异质性起源。单独来看,淋巴结转移病变的遗传特征在不同程度上与多个肺癌重叠,但与特定的肺部病变更为相关。SETD2 是 MPLC 的潜在转移生物标志物。原发肿瘤的假定新抗原数量平均值(646.5)高于淋巴结转移(300,p=0.2416)。原发性肺肿瘤和淋巴结转移在免疫谱上高度异质性。我们的研究结果描绘了 MPLC 伴 LNM 的全面基因组景观。我们描述了不同肿瘤之间的基因组异质性。我们为 MPLC 及其淋巴转移之间的克隆进化提供了新的线索,从而推进了 MPLC 伴 LNM 的治疗策略和预防。